Application of mesenchymal stem cell-derived exosome in preparation of medicine for preventing and treating hyperxia-induced type II alveolar epithelial cell injury
Through exosomes derived from mesenchymal stem cells, promote alveolar epithelial cell proliferation, inhibit ROS accumulation and autophagy, regulate the expression of related proteins, solve the problem of hyperoxygen-induced alveolar epithelial cell damage, and provide an effective oxygen therapy protection mechanism.
Patent Information
- Application Number
- CN202411028800.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-29
AI Technical Summary
The existing technology has not yet effectively solved its protective mechanism during oxygen therapy due to type II alveolar epithelial cell damage and autophagy caused by hyperoxygenic environment.
Using exosomes derived from mesenchymal stem cells to promote proliferation of type II alveolar epithelial cells, reduce ROS accumulation, inhibit autophagy, and prevent hyperoxygen induction by regulating the expression of GPX4, SLC7A11, Wnt 1, β-catenin and p62. Type II alveolar epithelial cell injury.
It significantly improved the proliferation ability of type II alveolar epithelial cells induced by hyperoxygen, reduced ROS accumulation and autophagy, provided a protective effect on hyperoxygen damage, and provided a theoretical basis for clinical application.
Smart Images

Figure CN119033815A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to the use of exosomes derived from mesenchymal stem cells in the preparation of drugs for preventing and treating hyperoxia-induced type II alveolar epithelial cell damage. Background Art
[0002] Oxygen therapy is widely used in the treatment of patients with respiratory failure and hypoxemia. It plays a vital role in saving lives, preventing multiple organ failure caused by hypoxia, and buying time for emergency treatment. However, hyperoxia can also cause oxygen toxicity. Long-term exposure to hyperoxia can cause acute lung injury (ALI) in adults and bronchopulmonary dysplasia (BPD) in infants and young children, and significantly increase the risk of acute respiratory distress syndrome (ARDS), which is also one of the causes of death. Long-term hyperoxia exposure can lead to the destruction of the alveolar-capillary barrier and changes in alveolar structure, and cause massive apoptosis of alveolar epithelial cells. Therefore, it is crucial to clarify the pathogenesis of this disease and implement appropriate lung protection measures during oxygen therapy.
[0003] Studies have shown that type II alveolar epithelial cells (AECⅡ) are stem cells of lung tissue and can differentiate into other lung tissue cells, but hyperoxia has been shown to promote cell apoptosis and excessive differentiation of AECⅡ cells into AEC I. After AECⅡ cells are damaged and apoptotic, their self-repair ability is limited, which can easily lead to alveolar structural damage and pulmonary fibrosis. Therefore, the supplementation of exogenous cells plays an important role in the repair of damaged alveolar epithelial cells.
[0004] Mesenchymal stem cells (MSCs) are a group of adult stem cells derived from tissues such as bone marrow, adipose tissue and umbilical cord, which have the ability to self-renew, multi-lineage differentiation and promote tissue repair. In recent years, there have been more and more reports on the therapeutic effects of MSCs on lung injury diseases. They have antibacterial, anti-inflammatory, tissue regeneration, anti-fibrosis, anti-oxidative stress and anti-apoptosis properties, which have opened up new avenues for the treatment of lung injury. Although MSCs have certain advantages in immunogenicity, in vitro expansion ability, genetic characteristics and acquisition methods, they also have potential defects such as tumorigenicity, embolism and teratogenicity after transplantation, and there are still many controversies in clinical treatment. In recent years, studies have found that MSCs mainly exert their therapeutic effects by secreting exosomes, which have similar biological functions to maternal cells, such as anti-inflammatory, tissue regeneration, anti-apoptosis and anti-fibrosis. However, compared with MSCs, exosomes are smaller in size, have a lower risk of embolism and lower immunogenicity. Their specific surface receptors allow them to deliver drugs or specific components to target cells. Due to these advantages, exosomes have broad application prospects in lung injury and are currently a research hotspot in the field of stem cells.
[0005] Mesenchymal stem cell-derived exosomes have been shown to have protective effects similar to MSCs themselves in cardiovascular disease, osteoarthritis, wound healing, various acute kidney injury animal models, and stroke rat models. However, their role in hyperoxia-induced type II alveolar epithelial cell injury and its potential mechanism have not been reported. Summary of the invention
[0006] In view of the above-mentioned problems, the present invention aims to provide the use of exosomes derived from mesenchymal stem cells in the preparation of drugs for preventing and treating hyperoxia-induced type II alveolar epithelial cell damage, and to explore the protective effects and potential mechanisms of exosomes derived from mesenchymal stem cells on ferroptosis and autophagy in hyperoxia-induced type II alveolar epithelial cell damage, so as to provide a theoretical basis for the clinical application of exosomes derived from mesenchymal stem cells.
[0007] In order to achieve the above objectives, the present invention provides, on one hand, the use of exosomes derived from mesenchymal stem cells in the preparation of a drug for preventing and treating hyperoxia-induced type II alveolar epithelial cell damage.
[0008] Furthermore, exosomes derived from mesenchymal stem cells promote the proliferation of type II alveolar epithelial cells, reduce the ROS accumulation of type II alveolar epithelial cells induced by hyperoxia, and inhibit the autophagy of type II alveolar epithelial cells induced by hyperoxia, thereby achieving the effect of preventing and treating hyperoxia-induced type II alveolar epithelial cell damage.
[0009] Furthermore, mesenchymal stem cell-derived exosomes increased the expression of GPX4 and SLC7A11 in type II pneumocytes induced by hyperoxia, thereby preventing and treating hyperoxia-induced type II pneumocyte damage.
[0010] Furthermore, mesenchymal stem cell-derived exosomes inhibited hyperoxia-induced autophagy of type II alveolar epithelial cells by increasing the expression of Wnt 1, β-catenin, and p62 and decreasing the expression of ATG5 and Beclin1.
[0011] Furthermore, the method for extracting exosomes derived from mesenchymal stem cells comprises the following steps: isolating bone marrow mesenchymal stem cells by a tissue cell adhesion method, culturing and amplifying them to the third generation, and obtaining exosomes from the supernatant of bone marrow mesenchymal stem cells by an ultracentrifugation method.
[0012] In addition, the present invention also provides a drug for preventing and treating hyperoxia-induced type II alveolar epithelial cell damage, wherein the drug comprises exosomes derived from mesenchymal stem cells.
[0013] The beneficial effects of the present invention are:
[0014] The present invention experimentally explored the protective effect and potential mechanism of mesenchymal stem cell-derived exosomes on ferroptosis and autophagy in hyperoxia-induced type II alveolar epithelial cell injury. The results showed that compared with the hyperoxia group, exosome treatment caused significant changes in the cell transcriptome; EdU detection results showed that compared with the control group, the hyperoxia group significantly reduced EdU positivity, and exosome treatment could alleviate this reduction. Compared with the control group, the hyperoxia group promoted ROS accumulation, while exosome treatment alleviated ROS accumulation. The results of immunoblotting showed that compared with the control group, the expression of GPX4 and SLC7A11 in the hyperoxia group was significantly reduced; while exosome treatment significantly increased the expression of GPX4 and SLC7A11. Immunofluorescence results showed that hyperoxia significantly increased LC3B positivity, while exosome treatment significantly reduced LC3B positivity. In the hyperoxia + exosome + 3-MA autophagy inhibitor group, the LC3B positivity rate was significantly increased. The results of immunoblotting showed that the hyperoxia group significantly reduced the expression of Wnt 1, β-catenin and p62, and significantly increased the expression of ATG5 and Beclin1, while the exosome treatment significantly increased the expression of Wnt 1, β-catenin and p62, and significantly reduced the expression of ATG5 and Beclin1. In the hyperoxia + exosome + 3-MA autophagy inhibitor group, the expression of Wnt 1, β-catenin and p62 was significantly reduced, while the expression of ATG5 and Beclin1 was significantly increased. The above conclusions indicate that exosomes derived from mesenchymal stem cells can reduce hyperoxia-induced type II alveolar epithelial cell damage by inducing cell proliferation, reducing ROS accumulation, inhibiting ferroptosis, and inhibiting autophagy, providing a theoretical basis for the clinical application of exosomes derived from mesenchymal stem cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 The morphology, size distribution and phenotypic identification results of the exosomes derived from MSCs in the present invention.
[0016] Figure 2 This is a transmission electron microscope photograph of the uptake of MSCs-derived exosomes by ACEⅡ in the present invention.
[0017] FIG3(A) is the cluster analysis result of differentially expressed genes in the present invention.
[0018] FIG3(B) is a volcano plot analysis result of differentially expressed genes in the present invention.
[0019] FIG. 4(A) is the GO analysis result of the differentially expressed genes in the present invention.
[0020] FIG4(B) is the result of KEGG pathway enrichment analysis of differentially expressed genes in the present invention.
[0021] FIG. 4(C) is a diagram showing the interaction relationship between differentially expressed genes in the present invention.
[0022] FIG. 5(A) shows the up-regulated genes in the sequencing results verified by the qPCR method in the present invention.
[0023] FIG5(B) shows the down-regulated genes in the sequencing results verified by the qPCR method in the present invention.
[0024] Figure 6 This is the result of the MSCs-derived exosomes promoting the proliferation of ACEⅡ cells in the present invention.
[0025] Figure 7 These are the results of ROS levels in ACEⅡ cells in different groups in the present invention and the expression of ferroptosis-related factors GPX4 and SLC7A11 in different groups.
[0026] Figure 8 The results of the cell immunofluorescence staining in the present invention were used to observe the number of LC3B spots in different groups of cells and the expression of autophagy-related proteins. DETAILED DESCRIPTION
[0027] In order to enable those skilled in the art to better understand the contents of the present invention, the corresponding experimental process and experimental results of the present invention are further described in detail below in conjunction with the accompanying drawings.
[0028] 1. Experimental Materials and Methods
[0029] 1.1 Experimental Materials
[0030] Lysis buffer, SDS-PAGE gel configuration kit, and 5× protein loading buffer were purchased from Beyotime Biotechnology. Trypsin, collagenase, deoxyribonuclease I, fetal bovine serum, and DMEM were all purchased from Gibco (USA). CD9, CD81, Nrf2, GPX4, SLC7A11, Wnt 1, β-catenin, p62, ATG5, and Beclin1 were all purchased from Abcam (UK). Trizol and M-MLV reverse transcriptase were purchased from Promega (USA). 3-MA was purchased from Selleck (USA). Ferrotropin 1 (Fer1), an inhibitor of ferroptosis, was purchased from Med Chemical Express. 4% paraformaldehyde was purchased from Beijing Ruier Xinde Technology Co., Ltd. The fluorescent probe 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) was purchased from Sigma-Aldrich.
[0031] 1.2 Extraction and identification of exosomes
[0032] Bone marrow mesenchymal stem cells were isolated by tissue cell adhesion method, cultured and expanded to the third generation, and exosomes were obtained from the supernatant of bone marrow mesenchymal stem cells by ultracentrifugation. In most studies, transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA) and Western blotting are generally considered to be the preferred methods for identifying exosomes. In this study, TEM, NTA and Western blotting were used to identify exosomes derived from mesenchymal stem cells.
[0033] Transmission electron microscopy: The extracted exosomes were diluted with an equal volume of phosphate buffered saline (PBS), dropped onto a 2 mm copper grid, and left at room temperature for 1 min. Excess liquid was gently removed with filter paper and stained with 3% uranyl acetate solution at room temperature for 5 min. After gentle rinsing with double distilled water, the grid was air-dried at room temperature, observed under a transmission electron microscope, and images were taken.
[0034] Nanoparticle tracking analysis: Dilute 10μL of exosomes to 30μL. First, use a standard sample to test the performance of the instrument. After the test passes, load the exosome sample and obtain the particle size information after the analysis is completed.
[0035] Immunoblotting: Immunoblotting was used to detect exosome surface markers.
[0036] 1.3 Uptake experiment of exosomes derived from mesenchymal stem cells
[0037] The mesenchymal stem cell-derived exosomes extracted in 1.2 were mixed with diluent C, and then the PKH-67 dye solution was quickly added, mixed with diluent C, and incubated for 15 minutes under light protection. The mixture was then placed on ice and 0.5% BSA was added to terminate the reaction. After centrifugation and extraction according to the instructions, a PKH-67-labeled MSCs-derived exosome suspension was obtained.
[0038] Type II alveolar epithelial cells (AECⅡ) were digested, resuspended, and counted. 100 μL of the cell suspension was mixed with an equal volume of PKH-67-labeled mesenchymal stem cell-derived exosome suspension and added to the bottom well of the confocal culture dish. The total number of cells was about 1×10 5 . Transfer the culture dish to the incubator and incubate for 1 hour before adding 2 mL of complete medium with a pipette. After 12 hours of incubation, prepare for imaging. Aspirate the culture medium, wash the cells three times with PBS, fix the cells with 4% paraformaldehyde (2 mL), leave them at room temperature for 10 minutes, and wash them again three times with PBS. Then stain the cell nuclei with DAPI (10 minutes). After removing DAPI, place the confocal culture dish on a horizontal shaker and wash it three times with PBS, each wash for 5 minutes. Remove the PBS, let the culture dish dry slightly, then carefully remove the glass bottom and place it on a slide. Observe the cells and image under a transmission electron microscope.
[0039] 1.4 RNA-seq high-throughput sequencing
[0040] Type II alveolar epithelial cells (AECⅡ) were divided into a hyperoxia group and a hyperoxia+MSCs-derived exosomes group. The cells in the hyperoxia+MSCs-derived exosomes group were treated with MSCs-derived exosomes under hyperoxic conditions. After modeling, the cells were collected and high-throughput sequencing was performed to identify genes that were significantly upregulated or downregulated in the hyperoxia+MSCs-derived exosomes group compared with the hyperoxia group. GO analysis and KEGG pathway analysis were performed on the differentially expressed genes to identify the related genes, and quantitative PCR was used to verify the high-throughput sequencing results.
[0041] 1.5 Real-time fluorescence quantitative PCR detection of relative mRNA expression of differentially expressed genes
[0042] Total RNA was extracted from cells using Trizol one-step method. Cells from different treatment groups were collected, chloroform was added, recovered for 15 seconds, and centrifuged after standing at room temperature for 2 minutes. The supernatant was transferred to a new PE tube, isopropanol was added, and after standing for 10 minutes, centrifuged. The supernatant was discarded and pre-cooled 75% ethanol was added for washing. After drying for 20 minutes, RNase-free water was added to completely dissolve the precipitate. Its concentration and purity were determined.
[0043] cDNA was synthesized by RT-PCR reverse transcription. The reaction system was then prepared according to the instructions of the real-time PCR kit and detected using a real-time fluorescence quantitative PCR instrument. The ΔΔCt value and relative quantity (RQ, where RQ = 2-ΔΔCt) were calculated using the internal reference as a control to determine the relative expression level of the target gene.
[0044] 1.6EdU detection of changes in cell proliferation in different groups
[0045] The cells were divided into a control group, a hyperoxia group, and a hyperoxia group + MSCs-derived exosomes group. The cells in the control group were cultured in normal complete medium, the cells in the hyperoxia group were cultured in complete medium under hyperoxic conditions, and the cells in the hyperoxia group + MSCs-derived exosomes group were treated with MSCs-derived exosomes in complete medium under hyperoxic conditions. After modeling, the complete medium was discarded, and a medium containing 50 μmol / L EdU was added for co-incubation for 2 h. The cells were fixed with 4% paraformaldehyde for 30 min, permeated with 0.5% TritonX-100 for 10 min, and washed with PBS. DAPI staining solution was added and incubated in the dark for 10 min. After washing with PBS, the cells were fixed with glycerol. The stained cells were observed under an inverted fluorescence microscope, and 5 random fields of view were selected to calculate the edu-positive cell rate. Blue fluorescence represents DAPI-stained cell nuclei (all cells), while red fluorescence represents edu-labeled proliferating cells. The cell proliferation rate was calculated as (number of red fluorescent cells / number of blue fluorescent cells) × 100%.
[0046] 1.7 Determination of exosome marker proteins (CD9, CD81), ferroptosis-related factors (GPX4, SLC7A11), and autophagy-related factors (Wnt 1, β-catenin, p62, ATG5, Beclin1)
[0047] After the hyperoxia group and hyperoxia + MSCs-derived exosome group were subjected to the corresponding hyperoxia treatment, the cells were washed three times with pre-cooled PBS and then lysed with RIPA cell lysis buffer for 30 min. The mixture was centrifuged at 12,000 rpm for 10 min at 4 °C. After BCA protein quantification, protein loading buffer was added in proportion, and the proteins were separated by SDS-PAGE electrophoresis and transferred to PVDF membrane. The membrane was blocked with 5% skim milk for 1 hour at room temperature and incubated with primary antibodies against CD9, CD81, GPX4, SLC7A11, Wnt 1, β-catenin, p62, ATG5, Beclin1 and GAPDH at 4 °C overnight. On the second day, the membrane was washed three times and incubated with the corresponding rabbit anti-secondary antibody for 1 hour at room temperature. ECL reagents were used for exposure and development of the automatic gel imaging system.
[0048] 1.8 Determination of ROS levels
[0049] The DCFH-DA probe (10 μmol / L) method was used to measure the level of cellular ROS. ACEⅡ cells treated with hyperoxia, hyperoxia + MSCs-derived exosomes, and hyperoxia + exosomes + ferroptosis inhibitor were cultured at 1×10 5The cells were seeded at a density of 10 μmol / L in a 6-well plate. After treatment, the cells were incubated with the probe molecule (10 μmol / L) at 37°C for 30 min, stained with staining solution for 2 min, and washed 3 times with PBS. Finally, fluorescence images of the cells were collected using a fluorescence microscope, and all images were analyzed using Image J software.
[0050] Immunofluorescence detection of LC3B puncta in 1.9 cells
[0051] Cells from different groups were seeded on slides, fixed with 4% paraformaldehyde for 15 min, washed with PBS, and permeabilized with 0.3% Triton X100 for 20 min. Cells were blocked with 5% BSA for 1 hour at room temperature and incubated with anti-LC3B primary antibody (1:1000) at 4°C overnight. After washing, cells were incubated with fluorescently labeled secondary antibody (1:1000) for 1 hour at room temperature. Cells were stained with DAPI and observed under a laser scanning confocal microscope, and LC3B spot images were scanned. The optical density values of the images were analyzed using Image J software, and the fluorescence intensity was calculated, where fluorescence intensity = optical density.
[0052] 2. Data processing
[0053] All data were processed using SPSS 29.0 statistical software. Continuous data were expressed as “mean ± standard deviation”. One-way analysis of variance was used for multiple group comparisons. For pairwise comparisons between groups, the LSD test was used for equal variances, and the Dunnett test was used for unequal variances. P < 0.05 was considered statistically significant. Images were processed using Image J 8.0.
[0054] 3. Experimental results
[0055] 3.1 Morphological and phenotypic characterization of MSCs-derived exosomes
[0056] The exosomes derived from MSCs were observed under a transmission electron microscope. The results are shown in the attached figure. Figure 1 As shown in A and B, the expression of exosome surface marker proteins was detected by immunoblotting as shown in the attached Figure 1 As shown in C.
[0057] From the attached Figure 1 It can be seen that the exosomes derived from MSCs are cup-shaped, with relatively uniform diameters, round or oval in shape, with membrane-bound vesicular structures, and contain dense cloud-like substances, which are the contents of the exosomes, such as attached Figure 1 As shown in Figure A. Nanoparticle tracking analysis showed that the diameter of exosomes ranged from 80 to 100 nm, as shown in the attached Figure 1 As shown in B. Western blotting results showed that markers CD9 and CD81 were expressed on the surface of exosomes, as shown in Figure 1 As shown in C.
[0058] 3.2ACEⅡ cells can take up MSCs-derived exosomes
[0059] In order to investigate whether type Ⅱ alveolar epithelial cells (AECⅡ) can take up MSCs-derived exosomes, this study used PKH-67 to label MSCs-derived exosomes.
[0060] PKH-67 is a green fluorescent biofilm tracking dye widely used in various in vivo or in vitro experiments. After co-culturing the labeled MSCs-derived exosomes with ACEⅡ cells, it can be observed that most cells have obvious green fluorescence around the nuclei. DAPI dyes the ACEⅡ nuclei blue, and PKH-67 marks the exosomes green. The merged image shows that the exosomes exist around the ACEⅡ nuclei with a high nesting rate. Figure 2 shown.
[0061] 3.3 MSCs-derived exosomes induce transcriptional changes of hyperoxia-induced ACEⅡ
[0062] The results of high-throughput sequencing showed that compared with the hyperoxia group, the hyperoxia + MSCs-derived exosomes group had 1,254 differentially expressed genes, including 684 upregulated genes and 570 downregulated genes, as shown in Figures 3(A) and 3(B), indicating that MSCs-derived exosomes treatment caused significant changes in the cell transcriptome.
[0063] Through GO analysis and KEGG pathway analysis, it was found that the differentially expressed genes were involved in the regulation of pathways such as MAPK signaling pathway, NF-κB signaling pathway, p53 signaling pathway, as well as biological processes such as RNA degradation, DNA repair, and cell cycle regulation, as shown in Figures 4(A), 4(B), and 4(C).
[0064] The quantitative PCR results showed that except for RIK, GM28118, MMP3, ATP2A3 and IGF2, the expression levels of other factors were basically consistent with the sequencing results. Among them, the expression changes of HSPA1A and NR4A1 were more significant, as shown in Figures 5(A) and 5(B).
[0065] The above results suggest that these factors play an important role in the protective effect of MSCs-derived exosomes against ACEⅡ injury.
[0066] 3.4 MSCs-derived exosomes promote ACEⅡ cell proliferation
[0067] ACEⅡ cells were treated with hyperoxia and then with MSCs-derived exosomes. Compared with the control group, the number of EDU-positive cells in the hyperoxia group was significantly reduced, while treatment with MSCs-derived exosomes alleviated this reduction, as shown in the attached Figure 6 This suggests that hyperoxia can inhibit cell proliferation, and MSCs-derived exosomes treatment can improve this.
[0068] 3.5 MSCs-derived exosomes alleviate hyperoxic injury to ACEⅡ by reducing ROS accumulation and inhibiting ferroptosis
[0069] After ACEⅡ was treated with hyperoxia and then exosomes, the results showed that hyperoxia promoted the accumulation of ROS in cells, while the exosomes treatment group reduced the accumulation of ROS compared with the hyperoxia group. Figure 7 As shown in A.
[0070] The expression results of ferroptosis-related factors GPX4 and SLC7A11 in different groups are shown in the Appendix. Figure 7 As shown in B and C. The expression of GPX4 and SLC7A11 was significantly decreased in the hyperoxia group. However, the expression of GPX4 and SLC7A11 was significantly increased in the hyperoxia + MSCs-derived exosomes group. In the hyperoxia + MSCs-derived exosomes + ferroptosis inhibitor group, the expression of GPX4 and SLC7A11 was significantly decreased.
[0071] 3.6 MSCs-derived exosomes regulate ACEⅡ cell injury through autophagy
[0072] The immunofluorescence results of ACEⅡ after hyperoxia treatment and then MSCs-derived exosomes treatment are shown in the attached figure. Figure 8 As shown in the attached Figure 8 As can be seen in Figure 3, hyperoxia induced a significant increase in LC3B-positive cells, while treatment with MSCs-derived exosomes led to a significant decrease in cytoplasmic LC3B-positive cells. Treatment with the autophagy inhibitor 3-MA significantly increased LC3B-positive cells, as shown in the attached Figure 8 As shown in A.
[0073] Immunoblotting analysis showed that hyperoxia treatment significantly reduced the expression of Wnt 1, β-catenin and p62, while significantly increased the expression of ATG5 and Beclin1. After MSCs-derived exosomes were treated, the expression of Wnt 1, β-catenin and p62 increased significantly, while the content of ATG5 and Beclin1 decreased significantly. At the same time, the autophagy inhibitor 3-MA significantly reduced the expression of Wnt1, β-catin and p62, while significantly increased the expression of ATG5 and Beclin1, as shown in the attached Figure 8 These results indicate that MSCs-derived exosomes can affect cellular autophagy.
[0074] In summary, hyperoxic injury significantly reduced the proliferation of type II alveolar epithelial cells, promoted the accumulation of ROS, exhibited the characteristics of ferroptosis, and increased autophagy. Increased apoptosis of AECⅡ cells can affect alveolar surface tension, leading to impaired alveolar ventilation and gas exchange. Therefore, during oxygen therapy, reasonable intervention measures should be taken to prevent and treat hyperoxia-induced lung injury, including targeted regulation. Under hyperoxic conditions, MSCs-derived exosomes can significantly improve cell proliferation, reduce ROS accumulation, and inhibit ferroptosis and autophagy.
[0075] Hyperoxia induces the production of ROS, upregulates the expression of LC3B, activates autophagy, and inhibits the Wnt / β-catenin signaling pathway. When hyperoxia damages lung epithelial cells, MSCs-derived exosomes may promote ACEⅡ proliferation, reduce ROS accumulation, inhibit ferroptosis and autophagy, thereby reducing cell apoptosis and alleviating the damaging effect of hyperoxia on ACEⅡ. Therefore, MSCs-derived exosomes have potential application value in the treatment of hyperoxia-induced acute lung injury.
[0076] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. Application of exosomes derived from mesenchymal stem cells in the preparation of drugs for preventing and treating hyperoxia-induced type II alveolar epithelial cell damage.
2. The use according to claim 1, characterized in that: Mesenchymal stem cell-derived exosomes promote the proliferation of type II alveolar epithelial cells, reduce the ROS accumulation of type II alveolar epithelial cells induced by hyperoxia, and inhibit the autophagy of type II alveolar epithelial cells induced by hyperoxia, thereby achieving the effect of preventing and treating hyperoxia-induced type II alveolar epithelial cell damage.
3. The use according to claim 2, characterized in that: Mesenchymal stem cell-derived exosomes increase the expression of GPX4 and SLC7A11 in type II alveolar epithelial cells induced by hyperoxia, thereby preventing and treating hyperoxia-induced type II alveolar epithelial cell damage.
4. The use according to claim 2, characterized in that: Mesenchymal stem cell-derived exosomes inhibited hyperoxia-induced autophagy of type II alveolar epithelial cells by increasing the expression of Wnt1, β-catenin, and p62 and decreasing the expression of ATG5 and Beclin1.
5. The use according to claim 1, characterized in that: The method for extracting exosomes derived from mesenchymal stem cells comprises the following steps: separating bone marrow mesenchymal stem cells by adopting a tissue cell adhesion method, culturing and amplifying them to the third generation, and obtaining exosomes from the supernatant of bone marrow mesenchymal stem cells by adopting an ultracentrifugation method.
6. A drug for preventing and treating hyperoxia-induced type II alveolar epithelial cell damage, characterized in that: The drug includes exosomes derived from mesenchymal stem cells.
Citation Information
Cited By
Research method for influence of LncRNA gad7 on alveolar type II epithelial cells in HALI and application
CN115896033A
